Su et al. analyzed a cohort of 103 patients harboring different KRAS mutation subtypes: G12A, G12C, G12D, and G12V, and evaluated differences in immunotherapy benefits among different KRAS subtypes in lung cancer. This evidence concerns the gene KRAS and lung carcinoma.